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Hepatic encephalopathy can be a serious complication of acute liver failure and chronic liver diseases, predominantly liver
cirrhosis. Hyperammonemia plays the most important role in the pathogenesis of hepatic encephalopathy. The brain-blood
barrier disturbances, changes in neurotransmission, neuroinflammation, oxidative stress, GABA-ergic or benzodiazepine pathway
abnormalities, manganese neurotoxicity, brain energetic disturbances, and brain blood flow abnormalities are considered to be
involved in the development of hepatic encephalopathy. The influence of small intestine bacterial overgrowth (SIBO) on the
induction of minimal hepatic encephalopathy is recently emphasized. The aim of this paper is to present the current views on
the pathogenesis of hepatic encephalopathy.
1. Introduction
Hepatic encephalopathy (HE) is a spectrum of neuropsychi-
atric abnormalities seen in patients with liver dysfunction
after exclusion of other known brain diseases [1]. It can
be the result of: acute liver failure, portosystemic bypass
without hepatocellular disease or liver cirrhosis, and portal
hypertension or portosystemic shunts [1]. HE manifests by
the broad spectrum of neuropsychiatric disturbances such
as: defects in cognitive, emotional, behavioral, psychomotor,
and locomotive functions [2]. The diagnosis of overt HE
is based on clinical examination. The diagnosis of minimal
hepatic encephalopathy (MHE) is difficult and is based on
psychometric tests [3, 4]. MHE is defined as a condition in
which in patient with liver cirrhosis (regardless of etiology)
the number of measurable neuropsychiatric disorders is
found at a normal mental and neurologic status to clinical
examination [5]. MHEwas previously called early, low grade,
latent, or subclinical hepatic encephalopathy [6].
2. Epidemiology of Hepatic Encephalopathy
Symptoms of overt HE are reported in approximately 30–
45% of patients with liver cirrhosis and 10–50% of patients
with transjugular intrahepatic portosystemic shunts (TIPS)
[7]. Incidence of MHE is estimated by various authors at
about 30–84% of patients with liver cirrhosis, depending on
the applied diagnostic methods and examined population
[6, 8, 9]. Romero-Go´mez et al. studies have shown the
presence ofMHE at 53% of examined cirrhotic patients, 30%
developed overt encephalopathy in the course of observation,
whereas 84% of patients with overt encephalopathy had
MHE in the history of disease [10]. Incidence of MHE in
Polish population of patients with liver cirrhosis is estimated
at 17,6–31.3% [11].
Predisposing factors for the development of HE are
alcohol consumption, high levels of ammonia, zinc and
branched chain amino acids, the presence of esophageal
varices, and MHE [10]. Electrolyte abnormalities, bleeding
into the gastrointestinal tract, infections, high protein diet,
diuretics, and sedatives may stimulate the development of
HE [12].
Patients with HE can present a number of clinical
symptoms, which intensity increases with the progress of HE,
such as: changes in personality, impaired sleep-wake cycle,
attention, concentration, cognitive, and motor functions,
such as psychomotor slowing, asterixis [1, 13, 14]. These
symptoms can be present chronically, and exposure to factors
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stimulating the development of HE can lead to coma and
death [15].
3. Pathogenesis of Hepatic Encephalopathy
According to previous studies, hyperammonemia is the main
factor responsible for the brain abnormalities in HE [16, 17].
Several mechanisms that explain the influence of ammonia
on the central nervous system (CNS) have been proposed
such as: specific interactions between brain endothelium and
astrocytes, modification of transport across the blood-brain
barrier, changes in energy metabolism, a direct neurotoxic
effect on astrocytes, and neuronal membranes, reducing the
synthesis of free glutamate with glutamatergic neurotrans-
mission disorder [18–20].
Ammonia is a major substrate for a number of enzymatic
reactions in the brain and is also a product of some
other reactions [17]. Children with congenital urea cycle
enzyme defect have the high serum ammonia concentration,
which—if left untreated—leads to the development of severe
neurological symptoms, seizures, and coma, and at those
who survived to mental retardation and paralysis of the brain
[17]. A full urea cycle takes place in the liver, although some
of the steps may be carried out in other tissues, including
the brain [17]. It was shown that in the liver cirrhosis, the
activity of urea cycle enzymes and glutamine synthetase in
the brain decreases [17, 21]. As the brain is not equipped with
an effective urea cycle, the ammonia is removedmainly in the
process of glutamine (Gln) synthesis from glutamate (Glu)
and ammonia, with the participation of glutamine synthetase
localized almost exclusively in astrocytes [22]. Astrocyte
swelling secondary to Gln osmotic effects consequently leads
to the brain edema [23]. Hence the conception of the therapy
with brain glutamine synthetase inhibitor is discussed [24].
Ammonia influences also other mechanisms leading to
development of hepatic encephalopathy such as: impaired
blood-brain barrier, changes in neurotransmission, proin-
flammatory cytokines, oxidative stress, abnormalities in
GABA-ergic or benzodiazepine pathways, impaired energy
metabolism of the brain, and impaired cerebral blood flow
[6, 19, 25–27].
3.1. Ammonia and Blood-Brain Barrier. Blood-brain barrier
(BBB) is formed by the endothelial cells that line cerebral
microvessels [18, 28]. BBB plays an important role in the
regulation of brain microenvironment homeostasis neces-
sary for a stable and coordinated neuronal activity [29]. It
protects the brain from harmful factors such as fluctuations
in the blood plasma components and neurotransmitters,
penetration of xenobiotics and toxins [29, 30]. BBB enables
the selective transport of substances from the blood to
the brain by diffusion and active transport across the
endothelial cells [29, 30]. BBB plays a key role in supplying
nutrients to the brain and removing unnecessary products,
regulates ion homeostasis, and allows to maintain a separate
pool of neurotransmitters and neuroactive substances in
the CSN, in peripheral tissues and in the blood [18, 31,
32]. A number of substances such as ammonia, serotonin,
bradykinin, adenosine, purine nucleotides, interleukins, free
radicals, nitric oxide, and steroids may influence the brain
endothelium function and tightness of BBB [18, 25].
Ammonia is a neurotoxin responsible for HE develop-
ment via a direct effect on the metabolism and functions of
the CNS and influencing the passage of various molecules
across the blood-brain barrier, transport of branched chain
amino acids, and aromatic amino acids (AA), which inflow
is increased due to the formation of Gln in the process of
ammonia detoxification [25].
Disturbances of AA transport affect the brain cate-
cholamine synthesis (serotonin and dopamine) and the
production of “false neurotransmitters” (octopamine and
fenylethylamine), resulting in impaired GABA-ergic, sero-
tonergic, and glutamatergic neurotransmission [15, 25].
3.2. Hyperammonemia and Acute Liver Failure. In the acute
liver failure (ALF), which can be the result of hepatotropic
viral infection or toxic injury, liver detoxification function is
abruptly reduced due to the massive necrosis of hepatocytes.
This leads to the hyperammonemia and development of
HE, characterized by rapid progression of symptoms from
discrete changes in mental status to stupor and coma.
Neuropathological studies revealed that the main cause
of death in ALF was cerebral herniation with brain edema as
the result of astrocyte swelling [33–36].
Pathogenesis of astrocytes swelling in the ALF is not fully
understood. Hyperammonemia, brain congestion, inflam-
mation in brain tissue, and systemic inflammatory response
play an important role in astrocyte swelling [36]. At the
initial stage patient has a normal or elevated intracranial
pressure, which can be “controlled” using mannitol, but fur-
ther progression of liver failure leads to step “uncontrolled,”
requiring liver transplantation [37].
A number of animal studies evaluating blood-brain
barrier integrity in the ALF have been carried out. The results
indicate a multifactorial mechanism of encephalopathy and
cerebral edema, in the pathogenesis of which the blood-brain
barrier impairment is essential [38–43].
There are much less research on this subject carried out
in humans.
Tofteng and Larsen using cerebral microdialysis tech-
nique studied biochemical changes in the brain of the patient
with ALF during liver transplantation [44]. They showed an
increase lactate concentration in the extracellular space with
the proper saturation and increased glutamate and glycerol
concentrations that have decreased after the transplantation.
This indicate disturbances in glutamate neurotransmission
and the lactate flow through the blood-brain in ALF [44].
Kato et al. examined brain biopsies of 9 patients who
died of ALF using scanning electron microscopy and showed
the presence of changes indicating that cytotoxic mechanism
with cellular edema seems to be the main cause of the
brain edema [45]. Vasogenic mechanism with impaired
permeability of the BBB appears to be less important in the
development of cerebral edema in ALF [45].
Kumar et al. analyzed the influence of arterial hyper-
ammonemia on complications and outcomes in a group of
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295 patients with ALF [46]. They found that persistent
arterial hyperammonemia increases the risk of complications
and mortality in patients with ALF [46]. Acute ammonia
neurotoxicity, that can provoke seizures in patients with ALF
is the result of increased release of glutamate in the neuronal
synapses with excessive activation of glutamate receptors,
especially the NMDA (N-methyl-D-aspartic receptor) [47].
3.3. Neurotransmission in Hepatic Encephalopathy. Accord-
ing to Albrecht et al. in HE associated with chronic liver dis-
ease, there is an imbalance between excitatory and inhibitory
neurotransmission [47]. Predominance of inhibition is
due to reduced expression of Glu receptors, resulting in
decreased glutamatergic tone [47]. Additionally, inactivation
of glutamate transporter GLT-1 in patients with hyperam-
monemia causes impaired Glu reuptake into astrocytes with
subsequent excessive extrasynaptic accumulation of Glu [47].
γ-aminobutyric acid (GABA) is another factor increas-
ing inhibitory neurotransmission through various mech-
anisms: increased levels of endogenous benzodiazepines,
increased availability of GABA at GABA-A receptors due
to enhanced synaptic release of the amino acid, direct
interaction of increased level of ammonia with the GABA-
A-benzodiazepine receptor complex, and ammonia-induced
upregulation of astrocytic peripheral benzodiazepine recep-
tors (PBZR) [47].
Another hypothesis assumes that the HE can be due to
the inhibition of the complex GABA-benzodiazepine recep-
tor by benzodiazepine-like ligands, that have high affinity for
these receptors [48]. This theory can be confirmed by the
fact that use of flumazenil-competitive antagonist of benzo-
diazepine receptor significantly improves the clinical status
of patients [49].
3.4. Hyperammonemia and Neurosteroids. Hyperammone-
mia may also be responsible for the increase of neurosteroids
concentration [15, 50]. In experimental studies adding
ammonia to the culture of astrocytes, increases pregnenolone
level [51, 52].
Ahboucha et al. demonstrated increased concentration
of allopregnanolone strong inhibiting neurosteroide that
stimulates mitochondrial peripheral-type benzodiazepine
receptors (PTBR) in the brain of patients with HE [53].
The elevated neurosteroids level stimulating the GABA-A
receptors may be responsible for increased GABA-ergic tone
observed in HE [15, 54]. This mechanism may explain
reduced motor skills, coordination problems, psychomotor
slowing hypokinesia, and tremor observed in HE [55]. These
motor function disorders may disturb daily functioning of
patients [56].
3.5. Hyperammonemia andOxidative Stress. Hyperammone-
mia may also have a direct toxic effect on the membranes of
neurons [19]. Studies in patients with portosystemic anasto-
mosis showed a disproportionately high level of ammonia in
some regions of the brain such as cerebral cortex, which may
impair the integrity of astrocytes [20].
Study of Sinke et al. on astrocyte cultures proved
involvement of nuclear factor κB (NFκB), activated by
oxidative stress, in ammonia-induced astrocyte swelling. The
activation of NFκB was associated with increased inducible
nitric oxide synthase (iNOS) protein expression and the
subsequent generation of nitric oxide (NO) [57].
According to No¨renberg et al., oxidative stress induced
by ammonia is a major pathogenic factor in the ALF HE
pathogenic and causes a whole cascade of events leading to
cell swelling and brain edema [58]. However, encephalopathy
in chronic liver disease is not accompanied by cerebral edema
[58, 59]. Perhaps it is due to the fact that, together with
accumulation of water in astrocytes as the result of GLN
osmotic effect, the myoinositol (Ins)-organic osmolite is
released from astrocytes, so its concentration in astrocytes
decreases preventing change in the cell volume [60].
3.6. Hyperammonemia and Neuroinflammation. Neuroin-
flammation is a new element in the pathogenesis of HE
described in animal models, which seems to play an impor-
tant role in the development of cognitive impairment, that
can persist after liver transplantation [61].
Shawcross et al. study in patients with liver cirrhosis
have shown that inflammation and inflammatory medi-
ators may significantly modulate ammonia influence on
CNS (significant deterioration in psychometric test and
improvement after the resolution of inflammation) [62].
The inflammation is an important factor determining the
presence and severity of neuropsychological dysfunction in
MHE caused by ammonia, that is, more significant in more
severe inflammation [63].
A significant increase of TNF-α and IL-6 proinflamma-
tory cytokines in serum of patients with MHE was noticed
[26].
Alvarez et al. study on the astrocyte cultures indicated
that proinflammatory cytokines such as TNF-α, IL-1β, IL-6,
and IF-γ and ammonia induce increase of the mitochondria
permeability and may be an important factor in the patho-
genesis of HE [64].
Increased mitochondrial permeability transition results
in reduction of ionic gradients and enhance mitochondrial
dysfunction, leading to brain energetic disorders that could
be a potential target for therapy [64–67].
Ammonia has a neurotoxic effect on brain astrocytes,
additionally abnormalities in the cell energetic level and
oxidative stress intensify HE. Change of astrocyte mito-
chondrial membrane permeability under the influence of
ammonia and Gln may be an important mechanism for the
formation of cerebral disorders associated with HE [66, 67].
Neuropathological disorders in both acute and chronic liver
damage involve mainly astrocytes [68].
Astrocytes, constituing about 1/3 the of the cerebral
cortex volume and playing a crucial role in the blood-brain
barrier, are involved in maintaining electrolyte homeostasis,
remove free radicals, and are responsible for the delivery
of nutrients and neurotransmitter precursors to neurons
[69]. Astrocytes play the role in the maintenance of both
the ion concentration and the volume of water and thus
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the osmolarity of the extracellular space of the brain, and
due to large capacity and ability to adjust and maintain
a constant volume of the brain [68]. Hyperammonemia
causes swelling of astrocytes, microglia activation, and the
development of Alzheimer type II astrocytosis [70, 71].
Particularly change in astroglial morphology is characteristic
for HE: edema and the presence of cells having the phenotype
of Alzheimer’s type II astrocytes, with a simultaneous change
in the expression of genes encoding regulatory proteins
supervising energy state, the cells volume, and neurotrans-
mission [71].
Alzheimer type II astrocytes are found in the gray
matter and white matter of the brain and subcortical nuclei
and may have various forms suggesting hyperplasia [70].
Number of Alzheimer Type II astrocytes correlate with the
encephalopathy intensity [19, 70].
Studies using the electron microscope in an animal
model of portosystemic hepatic encephalopathy have shown
that astrocytes before coma characterizes increased amount
of cytoplasm, proliferation of mitochondria and endo-
plasmic reticulum, and glycogen accumulation in the cell
cytoplasm, while in a coma Alzheimer’s type II astrocytes
was observed with the presence of degenerative changes in
mitochondria and the presence of large pale nuclei with
visible nucleoli [72]. These observations may suggest that
ammonia initially induces astrocyte metabolic activity and
subsequently the development of gliopathy. The presence
of Alzheimer type II astrocytes may be responsible for
the irreversibility of the changes [50]. As a result of
exposure to ammonia, some profound changes occur in
astrocytes, concerning the uptake of neurotransmitters and
ions that change the properties of astroglial and causing its
dysfunction- primary gliopathy, resulting in encephalopathy
[33, 50, 70].
3.7. Ammonia and Brain Energy Metabolism. Another cause
of HE may be dysfunction of neurons as a result of
abnormal interactions between neurons and astrocytes and
impairment of brain energy metabolism [65, 67]. Ammonia
modifies transport of nitric oxide precursors, arginine, and
ornithine (amino acids binding ammonia) across the blood
brain barrier and affects the transport of energy substrate for
brain, creatine, and glucose [25].
Cerebral energy metabolism and the synthesis of Gln
depend on glucose supply to the brain, and the functional
activity of the brain depends on the degree of glucose util-
ization [73]. Changes of glucose utilization in the brain
were noticed in patients with liver cirrhosis: reduction in
the cerebral cortex and increase in the basal ganglia and
cerebellum, that could be responsible for cognitive dys-
function [74, 75].
Yazgan et al. reported significant reduction in blood flow
through the thalamus and increase the flow through the
frontal lobes of patients with cirrhosis compared with the
healthy volunteers [76]. Another study described redistribu-
tion of blood flow from the cerebral cortex to subcortical
areas in patients with liver cirrhosis [75]. Studies using
magnetic resonance imaging showed an increase in cerebral
blood flow and reduce the average flow time in the basal
ganglia and the thalamus in patients with MHE, which is
consistent with the concept of redistribution of blood from
the cortex to the basal ganglia [27].
The results of research on the role of the local blood flow
in the development of MHE are inconclusive.
3.8. Neurotoxic Effects of Manganese. There was also noticed
accumulation of toxins in the brain, including manganese,
which deposition in the basal ganglia might be the cause
of hyperintense signals on T1-images in magnetic resonance
imaging (MRI) [77–79]. In patients with liver cirrhosis who
have portocaval anastomosis or TIPS hyperintense signals
in the globus pallidus (88% of patients) as well as increase
serum manganese concentration (67% of patients), and
the extrapyramidal symptoms such as tremor, rigidity, and
akinesia (89% of patients) were noticed [80]. Disturbances
of manganese and other minerals homeostasis may account
for the cognitive impairment associated with liver cirrhosis
[81–83].
Kulisevsky et al. in brain MRI of patients with liver
cirrhosis apart from increased signals in the globus pallidus
found also brain atrophy, which did not correlate neither
with the patients’ age nor the disease duration and the
number of points in the Child-Pugh score [84]. The positive
correlation between the degree of brain atrophy and the level
of ammonia was noticed [84]. A case of a patient with 23-
year history of portocaval anastomosis (PCA) made after
the second bleeding from esophageal varices was described.
For 12 years, he had intense neuropsychiatric disorders and
progressive degeneration of the brain in the course of 12 years
of HE, with significant withdrawal after liver transplantation;
therefore, these conditions should not be a contraindication
for liver transplantation [85].
3.9. Small Intestinal Bacterial Overgrowth (SIBO) in the
Development of Hepatic Encephalopathy. Recently the role
of SIBO in the development of MHE has been emphasized
[86, 87].
Gupta et al. study demonstrated a high prevalence of
SIBO in patients with MHE (38.6%), giving evidence for
the prokinetics, nonabsorbable antibiotics and probiotics
therapeutic use [86].
Jun et al. found a very high prevalence of SIBO (81.3%)
in patients with liver cirrhosis and ascites, which may suggest
that SIBOmay be a high risk factor for bacterial translocation
in patients with ascites [87].
4. Conclusion
The pathogenesis of HE is complex and so far none of the
proposed hypotheses emphasize the role of hyperammone-
mia and inflammation, and the role of proinflammatory
cytokines, impaired neurotransmission, false neurotransmit-
ters, oxidative stress, changes in cerebral blood flow, or brain
energymetabolism does not completely explain all associated
phenomena.
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The results of research from last several years show the
key role of blood-brain barrier in the development of HE-
related disorders, but most of these are animal studies.
Therefore, it is necessary to develop some modern diag-
nostic methods that allow the assessment of human brain
metabolism.
Better understanding of the encephalopathy pathogen-
esis in patients with acute and chronic liver insufficiency,
early diagnosis of MHE, and new therapies based on this
knowledge would prevent the development of overt enceph-
alopathy and neuropsychiatric disorders.
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